P4‐118: Safety and Pharmacokinetics Following a Single Infusion of the Anti‐amyloid Monoclonal Antibody Ponezumab (pf‐04360365) in Patients With Mild‐to‐moderate Alzheimer's Disease: Final Results
Bibliographic record
Abstract
Ponezumab (PF-04360365) is a humanized anti-amyloid β monoclonal antibody in clinical development as a therapeutic agent to reduce brain amyloid burden and improve clinical outcomes in patients with Alzheimer's disease (AD). This randomized, double-blind, placebo-controlled, single-dose-escalation study (0.1-10 mg/kg) in 37 patients with mild-to-moderate AD examined the safety and pharmacokinetics of ponezumab following 2-hour intravenous infusion. Patients enrolled into one of five dosing cohorts, mg/kg (n, ponezumab/placebo): 0.1 (4/2); 0.3 (4/2); 1 (4/2); 3 (6/2); 10 (8/3). Those receiving 1 or 10 mg/kg underwent optional lumbar punctures at baseline and Day 29 post-dose. All patients completed this 1-year trial. Ponezumab was well tolerated with no drug-attributed SAEs. The most common AEs were URTIs (n = 6 ponezumab; n = 4 placebo), headaches (n = 8 ponezumab; n = 5 placebo) and GI upset (n = 6 ponezumab), all mild-to-moderate. No AEs were dose-related. One subject (10 mg/kg) experienced a mild hypersensitivity reaction. Another (0.1 mg/kg) demonstrated slight enlargement of a pre-existing midbrain lesion. ECGs and routine safety laboratory values including CSF measures were unremarkable. No evidence of new microhemorrhage, vasogenic edema or encephalitis was noted. The pharmacokinetic profile of ponezumab was linear across the 0.1-10 mg/kg range with mean terminal half-lives of ˜6 weeks. Two 10 mg/kg patients had low CSF ponezumab concentrations (˜0.5% of plasma values) at Day 29. A dose-dependent increase in plasma Aβ1-x response and mean 38% increase from baseline at Day 29 in CSF Aβ1-x (p = 0.002 vs placebo) for the 10 mg/kg dose were observed. Single-dose ponezumab is well tolerated over the 0.1-10 mg/kg dose range in patients with mild-to-moderate AD. The pharmacokinetic profile of ponezumab is linear with limited evidence for central penetration. A dose-dependent increase in plasma Aβ1-x is consistent with the hypothesized mechanism of action, with effect also seen on CSF Aβ1-x. Multiple-dose studies are ongoing.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.001 | 0.001 |
| Meta-epidemiology (narrow) | 0.001 | 0.000 |
| Meta-epidemiology (broad) | 0.001 | 0.001 |
| Bibliometrics | 0.000 | 0.000 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.001 | 0.001 |
| Open science | 0.001 | 0.000 |
| Research integrity | 0.001 | 0.001 |
| Insufficient payload (model declined to judge) | 0.002 | 0.001 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".